A Phase II Study of Bone Marker Assessment of Multiple Myeloma Patients Treated With AminoBisphosphonates
- Each participant will receive a single dose of zoledronic acid intravenously after the
- Participants will then return to the clinic once every month for 6 months and have the
following tests and procedures performed: Medical history update; physical exam; ECOG
Performance Status; blood tests; and urine tests.
- After 6 months there will be an end of study visit, where the following procedures will
take place: medical history update; bone marrow aspirate and biopsy; skeletal survey.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To assess the proportion of patients with urinary NTX levels less than or equal to 50nmol/mmol following a single dose of zoledronic acid.
Noopur Raje, MD
Massachusetts General Hospital
United States: Institutional Review Board
|Massachusetts General Hospital||Boston, Massachusetts 02114-2617|